The Sabin PDP has initiated development for a new therapeutic vaccine for Chagas disease that will be undertaken with partners in Mexico, where between two and six million people are infected with this leading cause of poverty in Latin America. Current efforts focus on the development of two vaccine candidate antigens that will ultimately comprise the first therapeutic vaccine for Chagas disease. The vaccine is being developed in partnership with Baylor College of Medicine and Texas Children’s Hospital.

The PDP has also initiated a new project in early pre-clinical stages for the selection and discovery of antigens appropriate to advance into the development process of a leishmaniasis vaccine. Initial antigen discovery is underway for a recombinant protein vaccine that will reduce the global incidence of leishmaniasis.